Fondazione Telethon Announces FDA approval of Waskyra(TM) (etuvetidigene autotemcel), a Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome

ROME, Italy, Dec. 10, 2025 /PRNewswire/ -- Fondazione Telethon announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Waskyra, an ex ...

New cancer therapy brings remission for patients with deadly T-cell leukemia

A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by ...
Santé log

Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 ...

Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an ...
Medscape

First AACR Pediatric Cancer Report Highlights Gains and Gaps

The report charts major advances in precision oncology and immunotherapy but also reveals stagnant survival for several ...